SSG
ENTA icon

Summit Securities Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Summit Securities Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,000
Closed -$18K – 455
2013
Q2 		$18K Buy
+1,000
New +$19.5K 0.01% 259

Other funds holding ENTA

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
AP
AlpInvest Partners Amsterdam, Netherlands $49.7M AUM 23.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SONJCPFA
State of New Jersey Common Pension Fund A Trenton, New Jersey $226M AUM 27.71% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Summit Securities Group's ENTA Position: Q3 2013 in Review

Summit Securities Group sold out of Enanta Pharmaceuticals (ENTA) in Q3 2013, closing a stake of 1,000 shares — an estimated $18K sold.

Summit Securities Group first reported a position in ENTA in Q2 2013 and held it in 1 quarter. The position peaked at $18K in Q2 2013. 54 funds tracked by Wall St. Rank hold ENTA as of Q3 2013.

  • Summit Securities Group reported no remaining Enanta Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Summit Securities Group sold 1,000 Enanta Pharmaceuticals shares in Q3 2013, an estimated $18K.
  • Summit Securities Group first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Summit Securities Group's Enanta Pharmaceuticals position peaked at $18K in Q2 2013.
  • 54 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2013.

Based on Summit Securities Group's 13F filing for Q3 2013, filed 1 Nov 2013.